Abstract: An asymmetric tetradentate metal complex of a N{circumflex over (?)}C{circumflex over (?)}C{circumflex over (?)}N comprising tetradentate ligand has a metal connected to binding sites which are connected to each other via three or four covalent bonds that can be either single or double bonds with bridging linkers reside between C{circumflex over (?)}C and C{circumflex over (?)}N moieties. These linkers result in three-dimension metal complexes with distorted square planar geometries. The four donor atoms coordinate to a metal center. Upon metal binding a 5-6-6 membered metallocycle is formed upon chelation including a first nitrogen donor bond, a first metal-carbon bond, a second metal-carbon bond, and a second nitrogen donor bond. The light emission from these metal complexes can be tuned by the ligand structure over the entire visible spectrum.

Abstract: Disclosed are stable, high-efficiency voltage-dependent color-tunable organic light-emitting diodes with a single emitter, such as tetradentate platinum (II) complex, having long operational lifetime. High-performance voltage-dependent color-tunable OLEDs with a single Pt [O{circumflex over (?)}N{circumflex over (?)}C{circumflex over (?)}N] emitter are fabricated. The emission color can be tuned from warm white to nature white or from orange to yellowish green upon the emitter used. Long-term operational stability and continuously variable color enable these color-tunable OLEDs to find applications in smart wearable devices.

Abstract: The disclosure relates to a method for separating circulating free nucleic acid (e.g., circulating free DNA, cfDNA) from capillary blood sample (e.g., capillary blood plasma) and methods of determining and/or assessing the risk of cancer in a subject.

Abstract: The present disclosure relates to methods of preparing circulating tumor DNA (ctDNA) reference samples including: inducing apoptosis in tumor cells to obtain DNA fragments and then extracting DNA from the tumor cells to obtain the circulating tumor DNA reference samples. The methods to prepare ctDNA reference samples disclosed herein are simple and easy to use, suitable for various tumor cells, and the variant information can be retained to simulate the ctDNA in animals. In some embodiments, the reference samples can facilitate assay calibration and evaluation.

Abstract: Provided are a system and a method for assembling a double-deck vehicle body. The system includes a vehicle body chassis support and an upper floor support. The vehicle body chassis support includes a crossbeam, end supports, and an intermediate support, where the end supports are arranged separately at two ends of the crossbeam, the intermediate support is arranged at the middle of the crossbeam, a height of the end supports is greater than a height of the intermediate support, an upper surface of the end supports and an upper surface of the intermediate support are configured to be closely fitted to a lower surface of a vehicle body chassis; and the upper floor support is detachably arranged on a vehicle body chassis for supporting an upper floor of the vehicle body.

Abstract: The present application relates to the field the field of bioinformatics. Specifically, the present application relates to a method, system, electronic device and computer-readable medium for predicting the source of a sample to be tested based on multi-omics and multidimensional plasma features and artificial intelligence.

Abstract: An asymmetric tetradentate metal complex of a N{circumflex over (?)}C{circumflex over (?)}C{circumflex over (?)}N comprising tetradentate ligand has a metal connected to binding sites which are connected to each other via three or four covalent bonds that can be either single or double bonds with bridging linkers reside between C{circumflex over (?)}C and C{circumflex over (?)}N moieties. These linkers result in three-dimension metal complexes with distorted square planar geometries. The four donor atoms coordinate to a metal center. Upon metal binding a 5-6-6 membered metallocycle is formed upon chelation including a first nitrogen donor bond, a first metal-carbon bond, a second metal-carbon bond, and a second nitrogen donor bond. The light emission from these metal complexes can be tuned by the ligand structure over the entire visible spectrum.

Abstract: This disclosure is related to methods and apparatus of processing sequencing data (e.g., reducing noise in sequencing data).

Abstract: This disclosure is related to methods for hepatocellular carcinoma (HCC) screening. In one aspect, the disclosure relates to methods of detecting an integration site of hepatitis B vims (HBV) viral DNA in the genome of a subject. The methods involve collecting a nucleic acid sample from the subject; enriching the nucleic acids comprising HIBV sequences in the sample by hybridizing the nucleic acid sample to probes for HIB V viral DNA; sequencing the enriched nucleic acids, thereby obtaining a plurality of sequencing reads; mapping the sequencing reads to both human genome and HBV genome; and detecting the integration site of HIBV viral DNA at the human genome.

Abstract: Provided are a system and a method for assembling a double-deck vehicle body. The system includes a vehicle body chassis support and an upper floor support. The vehicle body chassis support includes a crossbeam, end supports, and an intermediate support, where the end supports are arranged separately at two ends of the crossbeam, the intermediate support is arranged at the middle of the crossbeam, a height of the end supports is greater than a height of the intermediate support, an upper surface of the end supports and an upper surface of the intermediate support are configured to be closely fitted to a lower surface of a vehicle body chassis; and the upper floor support is detachably arranged on a vehicle body chassis for supporting an upper floor of the vehicle body.

Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.

Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.

Abstract: A mounting structure and a gear motor are disclosed. The mounting structure includes at least one first hole formed in a first component of the gear motor, at least one second hole formed in a second component of the gear motor, arranged coaxially with the first hole, and at least one expansion member extending into the first and second holes. The expansion member has an interference fit with one of the first and second holes, and has a transition fit with the other of the first and second holes. The present invention can effectively prevent falling off of the expansion member, and reduce the assembly difficulties of the gear motor as well as the degree of deformation of the expansion member during the assembly process.

Abstract: The invention provides molecular markers that are associated with the progression of chronic myeloid leukemia (CML), and methods and computer systems for monitoring the progression of CML in a patient based on measurements of these molecular markers. The present invention also provides CML target genes, and methods and compositions for treating CML patients by modulating the expression or activity of these CML target genes and/or their encoded proteins. The invention also provides genes that are associated with resistance to imatinib mesylate (Gleevec™) treatment in CML patients, and methods and compositions for determining the responsiveness of a CML patient to imatinib mesylate treatment based on measurements of these genes and/or their encoded proteins. The invention also provides methods and compositions for enhancing the effect of Gleevec™ by modulating the expression or activity of these genes and/or their encoded proteins.

Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.

Abstract: The invention provides molecular markers that are associated with the progression of chronic myeloid leukemia (CML), and methods and computer systems for monitoring the progression of CML in a patient based on measurements of these molecular markers. The present invention also provides CML target genes, and methods and compositions for treating CML patients by modulating the expression or activity of these CML target genes and/or their encoded proteins. The invention also provides genes that are associated with resistance to imatinib mesylate (Gleevec™) treatment in CML patients, and methods and compositions for determining the responsiveness of a CML patient to imatinib mesylate treatment based on measurements of these genes and/or their encoded proteins. The invention also provides methods and compositions for enhancing the effect of Gleevec™ by modulating the expression or activity of these genes and/or their encoded proteins.

Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.

Abstract: The present invention relates to sets of genetic markers whose expression is correlated with prognosis of breast cancer in individuals having breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate individuals having a good prognosis, e.g., no reoccurrence or metastasis within five years of initial diagnosis, and individuals having a poor prognosis, e.g., reoccurrence or metastasis within five years of initial diagnosis. The invention relates to methods of prognosis using these markers. The invention also relates to microarrays containing probes to these markers, and to kits containing ready-to-use microarrays and computer software for data analysis using the prognostic and statistical methods disclosed herein.

Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.

Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.